Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Female AYAs Experience Financial Hardship Associated with Cancer-Related Employment Disruption

October 20, 2020
By Hannah Slater
Article

This study indicated that the financial hardship associated with cancer-related employment disruption among female adolescent and young adults can be sizable, suggesting a need for interventions to aid this patient population.

The financial hardship associated with cancer-related employment disruption among female adolescent and young adults (AYAs) can be sizable according to a study published in Cancer, especially among women diagnosed at a younger age, Hispanic women, and those with caregiving responsibilities.1

Given these findings, assistance returning to work following treatment as well as workplace accommodation policies present as important opportunities to lessen financial hardship and improve cancer survivorship care among this vulnerable patient population.

“Our study addresses the burden of employment disruption and financial hardship among young women with cancer—a group who may be at particular risk for poor financial outcomes after cancer given their age and gender,” Clare Meernik, MPH, of the University of North Carolina at Chapel Hill, said in a press release.2 “Our findings highlight the need for effective interventions to promote job maintenance and transition back to the workforce after cancer treatment, as well as increased workplace accommodations and benefits, to improve cancer outcomes for young women.”

Responses to an online survey were collected from AYA cancer survivors identified through the North Carolina Central Cancer Registry and the Kaiser Permanente Northern/Southern California tumor registries. Of note, disrupted unemployment was defined as reducing hours, taking temporary leave, or stopping work entirely due to cancer. Financial hardship was defined as material conditions or psychological distress which developed because of cancer.

Of 1328 women eligible for study who were employed at the time of their diagnosis, women were a median age of 34 years at the time of diagnosis and 7 years from diagnosis at the time of the survey. Overall, approximately 32% of the cohort experienced employment disruption.

A considerable percentage of the patients studied reported financial hardship related to material conditions (27%) or psychological distress (50%). Further, in adjusted analyses, women with disrupted employment experienced a 17% higher burden of material conditions (95% CI, 10%-23%) and an 8% higher burden of psychological distress (95% CI, 1%-16%) compared with those who did not experience a disruption.

“The relationship between employment disruption and material conditions was particularly pronounced among women diagnosed at a younger age (aged <35 years) and Hispanic women, whereas the relationship between employment disruption and psychological distress was stronger among women aged 30 to 34 years, those who were 6 to 9 years after their diagnosis, and those acting as caregivers,” the authors added. “The findings of the current study also highlighted the severity of material conditions related to employment disruption: 24% of women with disruption borrowed or went into debt of at least $10,000 and 9% borrowed or went into debt of at least $25,000 compared with 9% and 2.5%, respectively, among women with no disruption.”

According to the investigators, the development of survivorship care interventions that promote self-management and assist with transitioning back to or remaining in the workforce following a diagnosis of cancer may help to alleviate or prevent the effects of employment disruption on financial hardship. Moreover, the effects of cancer-related employment disruption could also be diminished or prevented altogether with the implementation of more flexible work accommodations and sick leave policies.

Moving forward, researchers suggested future studies that examine employment and financial outcomes among AYA cancer survivors would benefit by assessing more detailed information regarding factors such as dependent status at the time of diagnosis, household income, health insurance throughout treatment, employer-provided sick leave benefits and other disability insurance, demands of unpaid caregiving roles, and a variety of indicators of financial hardship. Information such as this could be used to inform potential targets of intervention.

References:

1. Meernik C, Kirchhoff AC, Anderson C, et al. Material and Psychological Financial Hardship Related to Employment Disruption Among Female Adolescent and Young Adult Cancer Survivors. Cancer. doi: 10.1002/cncr.33190

2. Study Examines Cancer’s Effects on Young Women’s Employment and Finances [news release]. Published October 12, 2020. Accessed October 13, 2020. https://newsroom.wiley.com/press-releases/press-release-details/2020/Study-Examines-Cancers-Effects-on-Young-Womens-Employment-and-Finances/default.aspx

Recent Videos
4 experts in this video
5 experts are featured in this series
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
Related Content
Advertisement

Potential Biomarker May Predict Outcomes/Response in RCC

Potential Biomarker May Predict Outcomes/Response in RCC

Kyle Doherty
July 18th 2025
Article

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC

Russ Conroy
July 18th 2025
Article

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

Tim Cortese
July 18th 2025
Article

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.


Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
July 18th 2025
Article

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Related Content
Advertisement

Potential Biomarker May Predict Outcomes/Response in RCC

Potential Biomarker May Predict Outcomes/Response in RCC

Kyle Doherty
July 18th 2025
Article

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC

Russ Conroy
July 18th 2025
Article

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

Tim Cortese
July 18th 2025
Article

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.


Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
July 18th 2025
Article

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.